Inna N. Lavrentieva

Inna N. Lavrentieva

Auto-generated profile, based on publicly available information

Inna N. Lavrentieva

Morozovskaya children’s city clinical hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
VVV.V. Vdovin
V.V. Vdovin
MKM.V. Kosinova
M.V. Kosinova
EKE.V. Kalinina
E.V. Kalinina
SISamara Samara City Children’s Clinical Hospital No. 1 Named After N.N. Ivanova
Samara Samara City Children’s Clinical Hospital No. 1 Named After N.N. Ivanova
ABA.YU. Borozinets
A.YU. Borozinets
The main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). The active use of biotechnological methods in the production of recombinant drugs contributes to the development and registration of new FVIII drugs. The results of clinical trials of drugs in children usually include a limited number of patients for a specific period of time. Post-marketing observational studies provide additional information on the results of using a new drug in patients in clinical practice. The objectives of the study were to collect and analyze data on the efficacy and safety of domestic recombinant FVIII with a deleted B-domain, moroctocog alfa (Octofactor, GENERIUM JSC) in the treatment of adolescents aged 12–18 years with hemophilia A in routine clinical practice. Materials and methods of research: a prospective multicenter open-label observational study of the results of using the Octofactor in adolescents with hemophilia A (№ OCF-HPA-N01) included 24 male patients with severe hemophilia A aged 12 to 18 years (mean age 14,8±1,7 years), who received moroctocog alfa in routine clinical practice. Enrollment in the study was carried out after the signing of the informed consent form by the parent of the minor patient and the minor patient aged 14 to 18 years, taking into account the results of the screening examination. The follow-up period was 52±4 weeks, which, presumably, was sufficient to achieve at least 100 days of moroctocog alfa administration. To assess the effectiveness, we analyzed the incidence of spontaneous bleeding that occurred within 48–72 h after drug administration; the severity of spontaneous bleeding against the background of prophylactic treatment with moroctocog alfa, the number of injections and the dose of the study drug for prophylactic treatment, as well as for treatment at the request of one episode of bleeding, taking into account its severity; the researcher's determination of the response to treatment of acute hemarthrosis according to the scale of the World Federation of Hemophilia (2020). To assess safety, the frequency and characteristics of adverse events (AEs) associated with drug administration were analyzed, including the frequency of formation of an inhibitor to FVIII. Results: during the study, 59 bleedings were recorded, of which 21 (36%) were spontaneous and 38 (64%) were post-traumatic. Among spontaneous bleeding episodes, 5 (24%) episodes occurred within 48–72 hours after administration of the study drug. Spontaneous bleeding within 48–72 hours after administration of Octofactor was absent against the background of prophylactic treatment in most patients (81%) and was observed rarely during the observation period (1–3 times) in the remaining 19% of patients. The median number of bleeding within 48–72 h after study drug administration was 1 episode over the follow-up period. The proportion of mild to moderate bleeding was 97 [88; 100]% among all types of bleeding and 100 [84; 100]% among spontaneous bleeding within 48–72 hours after administration of the Octofactor drug. The median of a single dose of Octofactor for preventive treatment was 2000 [1500; 2000] IU or 31,7 [25,6; 38,5] IU/kg, and with treatment on demand ‒ 2000 [2000; 3000] IU or 34,1 [28,8; 38,5] IU/kg per single injection. To stop the resulting bleeding required 1 [1; 2] introduction in a single dose of 3000 [2000; 4000] IU; the average dose was 4490 ÷ 4993 IU. When doctors subjectively assess the response to treatment of acute hemarthrosis on the scale of the World Federation of Hemophilia, an excellent response was noted in 9 (27%) episodes, good and moderate ‒ in 2 (6%) and 22 (67%) episodes, respectively. Lack of response to treatment of acute hemarthrosis with moroctocog alfa was not revealed in the study. During the study, 23 AEs were recorded in 13 (54%) patients not related to the study drug. Conclusion: thus, the obtained results of the study indicates the efficacy and safety of the Octofactor both the prophylactic treatment and treatment of on-demand bleedings in 12 to 18 year old patients with severe hemophilia A.

12 August 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
VPV.Yu. Petrov
V.Yu. Petrov
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
VVV.V. Vdovin
V.V. Vdovin
PSP.V. Svirin
P.V. Svirin
ILI.N. Lavrentyeva
I.N. Lavrentyeva
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.

18 February 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
S3Saint Petersburg Saint Petersburg City Polyclinic No. 37
Saint Petersburg Saint Petersburg City Polyclinic No. 37
TAT.A. Andreeva
T.A. Andreeva
Vladimir LebedevVladimir Lebedev
Vladimir Lebedev
KHKrasnodar Krasnodar Krai Regional Children'S Clinical Hospital
Krasnodar Krasnodar Krai Regional Children'S Clinical Hospital
VVV.V. Vdovin
V.V. Vdovin
ABA.YU. Borozinets
A.YU. Borozinets
The aim of the study was to evaluate the efficacy, safety and pharmacokinetics of nonacog alfa (Innonafactor) in children aged 2 to 12 years with hemophilia B. Materials and methods: 15 patients (7.7±2.5 years ) were included in an open, multicenter, prospective, non-comparative clinical trial, of whom 12 were aged 6 to 12 years and 3 were aged 2 to 6 years. The efficacy of the drug was assessed against the background of the introduction of 45±10 IU/kg 2 times a week with an interval of 72–96 hours, the safety was assessed by the frequency and nature of adverse reactions. Results: 5 (22%) spontaneous and 18 (78%) post-traumatic bleedings were registered. The mean number of spontaneous bleeding within 72 hours after administration of nonacog alfa was 2±1.4. The average prophylactic dose was 47.74±6.47 IU/kg (Me 48.2 IU/kg). An average of 2.2±2.1 injections was required to stop a bleeding episode. 19 adverse events have been reported that are not related to nonacog alfa. Conclusion: the obtained data indicate the efficacy and safety of nonacog alfa in the study group of patients. Thus, the data obtained indicate the efficacy and safety of Innonafactor drug both for prophylactic treatment and for the relief of bleeding in patients aged 2 to 12 years with severe and moderate hemophilia B.

22 December 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ILI. N. Lavrentyeva
I. N. Lavrentyeva
VVV. V. Vdovin
V. V. Vdovin
VPV. Yu. Petrov
V. Yu. Petrov
PMP. A. Mordvin
P. A. Mordvin
TST. V. Shevchenko
T. V. Shevchenko
MKM. Yu. Kozlov
M. Yu. Kozlov
Surgeries in patients treated prophylactically with emicizumab (including surgical procedures with a high risk of postoperative bleeding) are not associated with higher risks or technical difficulties compared with operations in patients receiving standard replacement therapy. On the contrary, the presence of emicizumab in the blood and its maintenance of permanent basic hemostasis allow for the reduction of doses and infusion time of bypassing agents. Patients undergoing surgical procedures with a high risk of postoperative bleeding require an additional hemostatic treatment during the first two or three days after the surgery. Then the duration of hemostatic treatment should be determined individually. We recommend the use of recombinant activated factor VII for the prevention/control of postoperative bleeding in patients with hemophilia A with inhibitors who are currently receiving emicizumab or have received it in the past 6 months. If treatment with anti-inhibitor coagulant complex is required, the daily dose should not exceed 100 units/kg. Here we report the first case of laparoscopic appendectomy in an 8-year-old child with hemophilia A with inhibitors receiving prophylactic treatment with emicizumab. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

12 April 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
MTM.A. Timofeeva
M.A. Timofeeva
TAT.A. Andreeva
T.A. Andreeva
S3Saint Petersburg Saint Petersburg City Polyclinic No. 37
Saint Petersburg Saint Petersburg City Polyclinic No. 37
VVV.V. Vdovin
V.V. Vdovin
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
ABA.Yu. Borozinets
A.Yu. Borozinets
Currently, the main method of treatment for hemophilia A is replacement therapy with drugs of blood coagulation factors VIII (FVIII). As a result of the development of new production technologies, recombinant FVIII are increasingly used for the treatment of hemophilia A. The justification for the use of new drugs in pediatric clinical practice requires careful preparation and clinical research studies of their efficacy and safety. The aim of this study was to evaluate the efficacy, safety and pharmacokinetics (PK) of domestic B-domain deleted recombinant factor VIII of Moroctocog alpha (Octofactor, GENERIUM JSC) in a cohort of children with hemophilia A aged 6 to 12 years in the framework of phase III clinical study of moroktocoga alpha in children 2 to 12 years old with hemophilia A. Materials and methods of the research: the age cohort of 6 to 12 years olds of an open multicenter prospective noncomparative study included 27 male children with severe hemophilia A (mean age 8,3±1,9 years). The study was carried out sequentially in 2 stages. Stage I included the study of PK parameters in 22 patients after a single study drug dose of 50 IU/kg. At stage II, the efficacy and safety of the drug was assessed in patients of stage I, as well as in additionally included 5 patients who received the study drug dose of 30±10 IU/kg per day every 2–3 days for 22±1 weeks of treatment. To assess the efficacy, we analyzed the incidence of spontaneous bleeding that occurred within 48–72 h after drug administration; the number of injections and the dose of FVIII used for prophylaxis, as well as for treatment on demand of one episode of bleeding, taking into account its severity; number of patients with severe hemophilia A with residual FVIII activity >/=1% 48–72 h after drug administration; the investigator's overall assessment of response to therapy on the acute hemarthrosis response scale. The main indicators for the analysis of PK properties were the area under the «concentration-time» curve, the half-life, the elimination constant, the increase in activity, and the degree of recovery of activity. To assess safety, the frequency of formation of an inhibitor to FVIII, the dynamics of vital and laboratory parameters, the frequency and characteristics of adverse events (AEs) associated with the administration of the drug were taken into account. Results: the area under the FVIII-time activity curve in the region of 0–48 h (AUC0-48) and with exponential extrapolation to infinity (AUC0-inf) was 731,82±264,94%*h and 756,11±270,16%*h, respectively. The half-life (T1/2) was 10,32±2,27 hours. In the examined age group, 78 bleeding were recorded, of which only 27 (35%) were spontaneous, including 24 (30%) episodes that occurred during 48–72 hours after the administration of drug under investigation. Haemorrhage within 48–72 hours after administration of the Octofactor drug was absent or was observed rarely (1–3 times) against the background of prophylactic treatment in most patients (88%), the median number of bleeding within 48–72 hours after administration of the study drug was 2 episodes per observation period. The proportion of spontaneous bleeding was the smallest in patients receiving a single prophylactic doses of the study drug 2000–3000 IU (7% of all bleeding), the largest proportion of spontaneous bleeding was observed in patients receiving a single prophylactic doses of the study drug 1000–2000 IU (70% of bleeding). The average single dose of Octofactor for preventive treatment was 1290,4±458,6 IU or 39,12±7,79 IU/kg, for on-demand treatment – 1641,7±722,4 IU per single injection. Of the 78 reported bleeding episodes, 68 (87%) required the study drug administration for relief, while the remaining 10 bleedings were selfcontained. On average, to stop bleeding, it took 1,5±0,8 injections of the drug on demand, median doses were 1 [1; 2], and average doses were 2434,3±1501,7 IU. During the study, 37 AEs were recorded in 15 (56%) patients. At the same time, 36 AEs (97%) were not associated with the drug under investigation, and one AE (allergic reaction), according to the researchers, was associated with the use of the drug. Thus, the analysis of data indicates the efficacy and safety of the Octofactor drug both the prophylactic treatment and treatment of on-demand bleeding in 6 to 12 year old patients with severe hemophilia A.

17 October 2024 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
ATA. E. Tsygankov
A. E. Tsygankov
DGD. V. Gorokhov
D. V. Gorokhov
ISI. O. Shchederkina
I. O. Shchederkina
MLM. I. Livshits
M. I. Livshits
ILI. N. Lavrentieva
I. N. Lavrentieva
VGV. V. Gorev
V. V. Gorev
Introduction: Prevention of hemorrhagic disease in newborns (HDN) in recent years has significantly reduced the number of intracranial hemorrhages (ICH) associated with these pathologies and the most common etiological cause of hemorrhagic stroke in infants. However, the issues of intensive therapy for intracranial hemorrhages in young patients of various etiologies didn’t lose their relevance.Objective: Study of the peculiarities of approaches to intensive care in children with ICH. Material and methods: The medical documentation of 35 patients aged 21 days to 4 months with ICH of various etiologies from 2017 to 2021 was analyzed. Results: Due to the severity of their conditions, 83 % of patients required mechanical ventilation. In our case series of 29 children with vitamin K-deficient coagulopathy the mortality was 3.4 %. Cerebral vasospasm developed in 57.1 % of intracranial hemorrhage cases. The duration of stay in the intensive care unit and the duration of mechanical ventilation, in addition to the severity of the condition at admission, hemorrhagic shock and neurological deficit, were influenced by cerebral vasospasm and convulsive syndrome. Conclusion: A retrospective analysis of the results of the treatment of neonates with intracranial hemorrhages caused by a late form of HDN allowed us to identify factors affecting the severity of the condition and outcomes. Since the incidence of this severe pathology is relatively low, and the literature data are contradictory, the personal experience of each hospital is important.